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Abstract
Background: Testing for tumor specific mutations on routine formalin-fixed paraffin-embedded (FFPE) tissues may predict
response to treatment in Medical Oncology and has already entered diagnostics, with KRAS mutation assessment as a
paradigm. The highly sensitive real time PCR (Q-PCR) methods developed for this purpose are usually standardized under
optimal template conditions. In routine diagnostics, however, suboptimal templates pose the challenge. Herein, we
addressed the applicability of sequencing and two Q-PCR methods on prospectively assessed diagnostic cases for KRAS
mutations.
Methodology/Principal Findings: Tumor FFPE-DNA from 135 diagnostic and 75 low-quality control samples was obtained
upon macrodissection, tested for fragmentation and assessed for KRAS mutations with dideoxy-sequencing and with two Q-
PCR methods (Taqman-minor-groove-binder [TMGB] probes and DxS-KRAS-IVD). Samples with relatively well preserved DNA
could be accurately analyzed with sequencing, while Q-PCR methods yielded informative results even in cases with very
fragmented DNA (p,0.0001) with 100% sensitivity and specificity vs each other. However, Q-PCR efficiency (Ct values) also
depended on DNA-fragmentation (p,0.0001). Q-PCR methods were sensitive to detect #1% mutant cells, provided that
samples yielded cycle thresholds (Ct) ,29, but this condition was met in only 38.5% of diagnostic samples. In comparison,
FFPE samples (.99%) could accurately be analyzed at a sensitivity level of 10% (external validation of TMGB results). DNA
quality and tumor cell content were the main reasons for discrepant sequencing/Q-PCR results (1.5%).
Conclusions/Significance: Diagnostic targeted mutation assessment on FFPE-DNA is very efficient with Q-PCR methods in
comparison to dideoxy-sequencing. However, DNA fragmentation/amplification capacity and tumor DNA content must be
considered for the interpretation of Q-PCR results in order to provide accurate information for clinical decision making.
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Introduction
Based on accumulated knowledge about tumor biology, newer
drugs are meant to treat cancer in a more rational way than classic
chemotherapy, i.e., by targeting specific molecules and pathways
that are essential for promoting tumor growth, maintenance and
metastasis. In this context, EGFR, a HER family receptor tyrosine
kinase, has emerged as a major molecular target. Because EGFR
was considered to be involved in the pathogenesis of most epithelial
cancers [1], anti-EGFR drugs were anticipated to improve outcome
for millions of patients worldwide. In fact, though, these drugs
dramatically benefit only a small percentage of cancer patients,
based on the alterations concerning EGFR itself (e.g., specific
mutations targeted by small molecule tyrosine kinase inhibitors
[TKIs]) or molecules in the EGFR effector pathways (for example,
KRAS [official gene name: v-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog; aliases: KRAS2, RASK2] mutations hamper-
ing therapeutic EGFR antibodies and possibly TKIs as well). Of
note, success rates of as low as 5% correspond to hundreds
thousands of patients worldwide for the major cancer types (breast,
lung, colorectal). Hence, if aiming in a rational and beneficial use of
molecule targeting drugs it is necessary to identify patients who will
truly benefit from such treatments, thus limiting unnecessary
toxicities, treatment delays [2,3] and health care costs [4].
Patient selection is required for drugs that are labeled for a
certain molecular target when approved for clinical practice. A
recent development in this context concerns two anti-EGFR
antibodies, cetuximab and panitumumab, that have been labeled
for use in metastatic colorectal cancer (CRC) under the condition
that the tumor carries a wild-type KRAS gene [5,6]. This decision
was based on accumulating evidence showing that CRC patients
with KRAS mutant tumors do not benefit from treatments with
anti-EGFR antibodies [7,8,9,10,11]. Hence, patients with mutant
KRAS tumors are not eligible for treatment with these drugs; the
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the tumor when assessing the patient; the information provided for
clinical decision making must be accurate.
The recent 10-year history of diagnostic predictive tests on solid
tumors shows that successful patient selection for molecularly
targeted drugs is based on three main parameters: (a) biological
relevance of the molecular marker, (b) methodology chosen for the
investigation of the marker, and (c) template characteristics.
Starting with the latter, diagnostic tests for the assessment of any
marker at any molecular level (e.g., proteins – immunohistochem-
istry, mutations – DNA) are performed on routine diagnostic
tumor material, i.e., formalin-fixed paraffin-embedded (FFPE)
tumor tissue containing molecular templates suffering from protein
cross-linking with formaldehyde. The consequences of fixation,
embedding and extraction methods on nucleic acid retrieval from
FFPE tissues have well been recognized and described
[12,13,14,15,16], whereby formalin fixation may degrade nucleic
acids –a serious problem- but it also deactivates their destructing
nucleases –a stabilizing effect. Thus, while molecular templates
from FFPE tissues are of inferior quality as compared to their
frozen counterparts, these may still be useable for a lot of recently
developed methods for nucleic acid investigation, even microarray
profiling and wide genome scans, while the main advantage from
using molecular FFPE templates is accurate correlation of results
with tissue histology.
In regard to the first two parameters, although KRAS mutation
status is, in fact, a negative marker predicting for resistance, its
biological relevance seems well established: about 30–40% of
CRC carry mutations in this gene occurring early in colorectal
carcinogenesis [17,18,19]. When present, KRAS mutations result
in the constitutive activation of this EGFR signaling pathway thus
rendering attempts of blocking the extra-cellular part of this
receptor in vain [1]. The majority (.98%) of KRAS mutations in
CRC are point mutations located in two neighboring codons, 12
and 13, and can thus easily be targeted with PCR-based methods.
A variety of PCR methods, increasingly real time PCR (Q-PCR)
targeted mutation detection assays, are currently applied for
diagnostic KRAS mutation assessments [20,21], some of which
have already acquired the license for in vitro diagnostic (IVD) use
in Europe [22]. These methods are developed to overcome the
shortcomings of conventional dideoxy-sequencing, the as yet
golden standard for mutation assessment, namely labor, time and
expertise requirements, low sensitivity at 30% detection of mutant
cells in tissues and variously low efficiency on FFPE-DNA [23,24].
Indeed, Q-PCR methods are easy, fast and surpass the
requirement of ‘‘1% sensitivity’’ set for diagnostic mutation
assessments [21], while the infrastructure necessary to perform
these tests is increasingly acquired in diagnostic laboratories. Of
note, 1% sensitivity mostly concerns 1% selectivity, as explained
recently [25], while the 1% cut-off is set arbitrarily. At present,
although Q-PCR methods are in general more efficient than
dideoxy-sequencing on FFPE material, since they target small
sequences likely to be preserved upon formalin fixation, it is still
not clear how they perform on a daily routine basis in this context.
In comparison to research, where mutation investigations have
long been applied on FFPE-tissues, mutation assessment in the
diagnostic setting is distinctive in that (a) it is practically impossible
to interfere with general pathology practice issues, such as surgical
material processing or fixation and paraffin block storage
conditions, as suggested for research purposes [13], because the
FFPE material submitted to a molecular lab has usually been
originally processed elsewhere, and (b) the end-point is not
statistical significance upon comparison of different parameters but
a result that will aid in clinical decision making for the individual
patient. Because of (a), tumor cell content and sample DNA
degradation are parameters that can not be changed for a
submitted diagnostic material; because of (b), diagnostic samples
with ‘‘unfavorable’’ DNA quality or low tumor cell content can not
be lightly excluded from analysis.
Herein, we report on our experience on prospective diagnostic
KRAS mutation testing with three methods including dideoxy-
sequencing that was used as the reference method for mutation
validation, and two Q-PCR methods, the IVD DxS-KRAS test
and a Taqman-minor-groove-binder (Taqman-MGB, TMGB) test
that was standardized and validated in our lab, by taking into
consideration not only the efficiency of the methods but mostly
focusing on template characteristics.
Methods
Tissue specimens and processing
A total of 210 FFPE CRC specimens were evaluated in this
study upon permission from the Medical Ethics Review Board
(A9586/21-5-08), School of Medicine, Aristotle University Thes-
saloniki (AUTH). All patients had signed an informed consent
form for the use of their biologic material for diagnostic and
research purposes. CRC specimens (Table 1) were derived from
the following sources:
Group A (n=135) included material from patients with
metastatic CRC that was prospectively investigated for KRAS
codon 12 and 13 mutations to predict patient eligibility for
treatment with anti-EGFR antibodies, according to current
guidelines [5,6]. Samples in this group included paraffin blocks
from previously diagnosed (2001–2008) histologic material that
were referred for KRAS mutation testing to the Molecular Lab of
the Department of Pathology, AUTH. Tissue processing and
original histologic diagnoses had been undertaken in various
pathology labs in Greece. Because in our country the processing
practice for colectomy specimens does not include buffered
formalin, tissue fixation had been accomplished in the majority
of cases in simple formalin (,4% formaldehyde) for various time
points. Small specimens, such as punch or needle biopsies, were
usually fixed in buffered formalin. Overall, it was impossible to
interfere with- and to obtain detailed information on fixation
conditions for the majority of the tissues examined.
Paraffin blocks derived from colectomy specimens (n=98),
excision of metastatic sites (n=29, out of which 13 in the liver, 8
in the lung and 8 in other sites), and punch or needle biopsy
specimensfromthe primarytumoror from metastaticsites(n=8).In
all cases, histological confirmation for the presence of the previously
diagnosed tumor was performed by a pathologist, who also marked
the most dense tumor area on the H&E section avoiding as much as
possible necrotic and hemorrhagic areas and extracellular mucous
aggregates. These areas were subsequently macrodissected with a
scalpel from thick (10 um) deparaffinized sections and brought into
1.5 ml tubes for tissue digestion. The number of sections used per
case (3–8) varied according to the dissected area and to tumor
histology, necessitating less for more compact tumors.
Group B (n=75) included archived FFPE material from
patients with CRC from the Dept of Pathology, AUTH. This
material derived from colectomy specimens in 74 cases and in one
case from biopsy material from a local recurrence. Tumor areas
from these specimens had been carefully selected by a pathologist
to contain 50–90% neoplastic cells and were placed on TMAs
(1,5 mm core diameter). TMA core sections were used for DNA
extraction (in total, 30 um thickness per case). From each such
case 2000–3000 cells were anticipated. This group was used to
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analysis with different methods (unfavorable control group).
Anticipated tumor DNA content in FFPE tissue extracts
Samples containing .70% tumor cells, as estimated on a 2 um
thick H&E section are considered optimal for KRAS genotyping
[21]. Since genotyping is performed on genomic DNA, the nuclei
of these cells are of interest. One 10 um thick section from such a
specimen, however, would correspond to ,70% tumor nuclei,
since these are .10 um and disoriented (described in models for
FISH determinations [26]). By contrast, intact normal cell nuclei
are likely to be contained in such a section, since these are
substantially smaller in size. Hence, including .2 thick sections
will further change and eventually lower the percentage of tumor
DNA in the extract, even if an after-dissection H&E retains the
original analogies. In the same sense, for a specimen assessed to
contain 30% or 10% tumor cells on an H&E section, the
anticipated tumor DNA content in the extract will be unpredict-
ably different (lower, most probably). Thus, the histological
assessment of tumor cell percentage on an FFPE section can serve
only as a very rough estimate for tumor DNA content in the
corresponding extract. The approach is still necessary, however,
especially in samples with low tumor cell content, in order to
evaluate genotyping results with different methods. The percent-
ages shown in Table 1 are H&E estimates.
The above also justify the necessity for tumor cell enrichment
for genotyping assessments from FFPE tissues. Macrodissection as
described here and elsewhere [7,27] may be more suitable for
KRAS testing than the discussed detailed laser microdissection or
needle core dissection [20], because of the long proposed CRC
heterogeneity in KRAS mutation status [28,29] prompting for
extensive tumor area sampling.
DNA extraction and evaluation
DNA was extracted manually with the QIAamp DNA mini kit
[Qiagen, Hilden, Germany], according to the manufacturer’s
instructions. When necessary (biopsy and metastatic material,
mostly), glycogen was added into the lysates as DNA carrier, and
the final elution volume was reduced to half in order to obtain
more condensed DNA. Concentration (ug/ml) and absorbance
(A260/280 ratio) were measured in a UV spectrophotometer
[BioPhotometer, Eppendorf, Hamburg, Germany]. Fragmenta-
tion of the samples was assessed with the multiplex DNA control
assay from BIOMED2 [30], which includes testing for 5 different
DNA targets [100, 200, 300, 400 and 600 bp] in the same
reaction. Products were visualized on 2% agarose gels (Figure 1A).
The same assay was also used to assess FFPE-DNA integrity for
array-comparative genomic hybridization (aCGH) [31], while
similar testing is required before processing FFPE-DNA samples
for wide genome scans, for example, with Affymetrix platforms
[http://165.193.231.7/support/technical/technotes/copynum-
ber_ ffpe_technote.pdf].
Dideoxy-Sequencing for KRAS exon 2 (coding exon 1)
Primers located at intron 1 (forward: 59-tggtggagtatttgatagtgtat-
taac-39) and intron 2 (reverse: 59-cccaaggtacatttcagataactt-39)
spanning the entire exon 2 were used. PCR products (340 bp)
were always visualized on agarose gels and archived prior to
sequencing. Sense and antisense sequencing was performed in a
10 ul reaction with the Big Dye Teminator kit v.1.1 [Applied
Biosystems, Foster City, USA]. Sequences were visualized upon
capillary electrophoresis in an ABI3130 genetic analyzer, initially
called with the Sequencing Analysis software and further analysed
with the SeqScape software v2.5 [Applied Biosystems/Biosolu-
tions, Athens, GR]. All samples (groups A and B) were submitted
to PCR for dideoxy-sequencing.
KRAS Allelic Discrimination with Taqman-MGB assays
(KRAS-TMGB)
Minor grove binder (MGB) modifications at the 39-end of
sequence specific oligos provide the advantage of designing short
Table 1. FFPE sample characteristics in the diagnostic (A) and
in the unfavorable control group (B).
group A group B
block age (210 cases)
all samples 135 75
2005–2008 114 29
before 2005 21 46
percentage of tumor cells
.30% 105
& 75
&
.10–30% 24 none
,10% 6 none
DNA quantity (ug/ml)
mean 81,7 67,4
range (min–max) 12,3 to 383,5 12,5 to 147,3
A260/280 ratio
mean 1,67 1,27
range (min–max) 1,21 to 1,98 1,18 to 2,6
1,6–1,8 (n samples) 94/135 2/75
DNA fragmentation test (n
samples)
$300 bp (less fragmented) 102 (75,6%) none
100 & 200 bp (intermediate) 17 (12,6%) 2
100 bp or no product (heavily
fragmented)
16 (11,8%) 73
DNA control curve Ct
KRAS-TMGB (,50 ng/reaction)
n samples tested 135 75
mean* 28,46 34,06 p,0.0001
6SD* 2,71 2,07
range (min–max) 23,73 to 36,61 30,58 to 39,37
Ct #29** (n samples) 52 (38,5%) 0
Ct #33# (n samples) 128 (94,8%) 26 (34,6%)
DxS-KRAS (,50 ng/reaction)
n samples tested 29 66
meanˆ
31,61 36,60 p,0.0001
6SDˆ
3,49 2,78
range (min–max) 26,21 to 39,49 31,6016 to 40
Ct #29** (n samples) 8 (27,5%) 0
&=.50% tumor cells for 88 samples in group A and all samples in group B
*= values from all samples (n=210 for this test) for the DNA control assays
employed (7 assays)
**= Ct (Cycle threshold) limiting value for reliable highest sensitivity
assessments with each test (,0.7% mutant tumor cells with the KRAS-TMGB
and ,1% with the DxS-KRAS test, respectively)
# = Ct value for reliable assessments with a sensitivity of ,7% tumor cells
ˆ
= values from all samples tested (n=95 for this test) for the DNA control assay
employed (1 assay)
doi:10.1371/journal.pone.0007746.t001
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PLoS ONE | www.plosone.org 3 November 2009 | Volume 4 | Issue 11 | e7746Figure 1. FFPE DNA fragmentation and real time PCR method performance. A: A typical series of diagnostic samples tested with the
multiplex PCR assay for DNA fragmentation and KRAS exon 2 (intron spanning amplicon). Samples positive for products $300 bp are considered as
good quality samples yielding the 340 bp product for exon 2 KRAS sequencing. In lanes 1, 3 and 4, faint KRAS product bands could be obtained from
samples with very fragmented DNA but the corresponding capillary electropherograms were usually non-informative. In B, real time PCR efficiency
largely depends on DNA fragmentation. DNA control Ct values reflect the amplification efficiency of FFPE DNA. With both TMGB and DxS-KRAS
assays, Ct values from good quality samples were substantially lower than Ct values from very fragmented samples. The majority of FFPE DNA
samples yielded DNA control Ct values between 29–33 (dotted lines). In C, typical results from diagnostic samples with DxS-KRAS. DNA control Cts for
the standards contained in the kit are below 29 (arrow), but corresponding values for the diagnostic samples are .29.
doi:10.1371/journal.pone.0007746.g001
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duplex stability and specificity in comparison to conventional
Taqman probes [32], allowing for multiplexing and specific
mismatch identification as in the case of single nucleotide
polymorphisms (SNPs) [33]. The sensitivity and efficiency of
SNP-testing with Taqman-MGB probes in low-medium through-
put analyses has been well documented with good quality
molecular templates (DNA from peripheral blood, mostly) for
germline allelic discrimination or for strain identification of various
inflammatory agents [33,34,35,36,37], whereby these probes do
not differ in performance from LNA-probes [38]. A Taqman-
MGB assay has been shown as a very reliable alternative to
sequencing in identifying the BRAF V600E mutation in CRC
FFPE samples [39].
KRAS-TMGB assays were designed with the Primer Express
software v1.3 [Applied Biosystems] to detect the 7 more common
KRAS mutations in CRC (in alphabetical order, GLY12ALA
[G12A], GLY12ARG [G12R], GLY12ASP [G12D], GLY12CYS
[G12C], GLY12SER [G12S], GLY12VAL [G12V], GLY13ASP
[G13D]). The amplicons were set at 80 bp and the detected
sequence was: AGGCCTGCTGAAAATGACTGAATATAAAC
TTGTGGTAGTTGGAGCTGGTGGCGTAGGCAAGAGTG
CCTTGACGATACAGC (codons 12 and 13 are underlined).
Samples were run in duplicates of 20 ul reactions, each containing
one VIC labelled probe for the wild-type allele (endogenous DNA
control serving simultaneously as control for the amplification
capacity of the sample) and one specific FAM labelled probe for
the mutant allele (target). In the beginning of the application of this
assay, sequencing validated mutant samples were included in the
runs as controls for the amplification of the mutant allele.
Evaluation runs for DNA input and cut-off (sensitivity) assessments
were performed in triplicates.
Rationale for the evaluation of targeted mutation calling
with Q-PCR
As instructed by the manufacturer [Applied Biosystems] and as
described for the evaluation of Taqman-MGB SNP genotyping in
FFPE tissues [40], the presence of genotype variants is called upon
plate reading by the software. This may be useful for germline
inherited polymorphisms, where heterozygous alleles would be
expected to occur in equal amounts. Somatic single-base
substitution mutations like the ones found in human tumors in
KRAS codons 12 and 13 correspond to SNPs for the cells bearing
these mutations, which will appear as heterozygous by any testing
(1:1 ratio for the mutant vs wild-type alleles in mutant cells). In the
tissue context, however, the ratio of mutant vs wild-type alleles
depends on the presence of non-mutant cells in the sample and
would practically correspond to half the percentage of mutant
tumor cells. For example, in a sample containing 50% tumor cells,
provided that all of them were KRAS-mutant, the mutant alleles
to be amplified would correspond to 25% of all alleles included in
the sample, which is below the limit of heterozygous calling by the
SDS software. Hence, the evaluation of KRAS mutation status
was based on the cycle thresholds (Cts) of the wild-type and
mutant amplification curves and on the differences between these
Cts (dCts), whereby dCtA = (Ct for mutant target A) - (Ct for
DNA control coamplifying with mutant target A). For each mutant
target the respective coamplifying control was used in dCt.
External validation of KRAS-TMGB results
The same KRAS-TMGB assay was independently developed
previously [10] and used for KRAS mutation assessment in CRC
[7]. The test is currently used with identical primer/probe
sequences for 6 assays and with modified probe sequences for
the GLY12ALA assay in the Dept Human Genetics, Lab of
Digestive Oncology, University of Leuven. In order to further
validate our results with KRAS-TMGB, 106/135 of our
diagnostic samples (group A) were assessed for the presence and
type of KRAS mutations by the lab in Leuven.
Therascreen KRAS kit (DxS-KRAS)
This KRAS mutation detection system [DxS, Manchester, UK]
uses Scorpion primers designed specifically to recognize the
mutated sites (amplification refractory mutation screening
[ARMS]) with high efficiency and specificity. The DxS-KRAS
kit has been approved as IVD-device by the EMEA (European
Medicines Agency) for the identification and typing of the 7 most
common KRAS mutations [22]. For the purposes of this study,
this system was retrospectively used on 95 samples, following
analysis with sequencing and KRAS-TMGB. Samples were run in
25 ul reactions in the ABI7500 real time PCR system described
above. The threshold for analysis was set manually in the middle
of the DNA control amplification curve, separately for each run,
according to the manufacturer’s instructions, and dCt values were
obtained for (mutant target curve Ct) - (DNA control curve Ct).
No template controls and the standards provided by the
manufacturer were used in order to monitor results.
Result presentation and statistics
Statistics (descriptive, chi square, Mann-Whitney and Spear-
man’s correlation tests) were performed by using the SPSS v14 and
the GraphPad Prism v5 software; the latter was used for graph
presentations as well.
Colormaps of the relative quantification values were built using
MATLAB scripts in order to present dCt profiles for all cases
studied. Specifically, dCt values were normalized and approxima-
tions to 22 for the lower values and 5 for the highest were applied
in order to highlight the differences of the quantification values in
the mid-region.
Results
DNA sample characteristics from FFPE CRC tissue
material
DNA sample characteristics are shown in Table 1. In the
majority of cases, it was possible to obtain .30% tumor cells in the
DNA sample, a threshold set for dideoxy-sequencing sensitivity/
selectivity in tissues [21]. However, this threshold could not be
reached in 30 diagnostic samples (22%).
As measured with UV-spectrometry, values corresponding to
DNA quantity did not differ between groups A and B (Table 1);
the samples of the two groups, however, differed substantially in
the obtained absorbance values (A260/280 ratios), which
correspond to DNA purity (Mann-Whitney p,0.0001). Further,
samples in group B appeared heavily degraded in comparison to
those in group A (p,0.0001), as observed by their performance
with the multiplex PCR fragmentation test (Table 1). If comparing
all samples, the efficiency of the fragmentation test was related to
the A260/280 ratios and to block age (Mann-Whitney p=0.003
and p=0.010, respectively), in line with previous observations for
continuing nucleic acid degradation after fixed tissue embedding
[41].
In all samples yielding $300 bp products with the fragmenta-
tion test, amplification of single PCR targets for sequencing was
also successful; in addition, in some cases with very fragmented
DNA, single 340 bp KRAS products were obtained (Figure 1A).
However, sequencing was not always informative in these cases
(Table 2).
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methods on FFPE-DNA samples depends on DNA
fragmentation
Sequencing efficiency corresponds to informative nucleotide
(base) calling in the electropherograms obtained by the software
employed in each case. Sequencing efficiency was inversely related
to the degree of DNA fragmentation in both groups (p,0.0001),
and to a lesser extent to the A260/280 ratios in group A
(p=0.008) and to DNA input (p=0.032). The efficiency of this
method is shown in Table 2. Yielding the 340 bp KRAS product,
as observed upon agarose gel electrophoresis (Figure 1A),
conferred to the samples eligibility for further processing for
sequencing (86,1% informative results from eligible samples). In
28/135 cases (20.7%) we repeated the whole procedure (DNA
extraction and PCR) in order to obtain better quality templates.
This attempt yielded PCR products and interpretable electrophe-
rograms in only 4 additional cases.
The efficiency of Q-PCR methods is reflected in the Ct (cycle
threshold) values obtained for the DNA control target included in
each test, whereby (a) the higher the Ct the lesser amplifiable DNA
in the sample, and (b) appropriate setting of the reading threshold
is very important when using open systems, such as the ABI7500
instrument [http://www3.appliedbiosystems.com/cms/groups/
mcb_marketing/documents/generaldocuments/cms_042502.pdf].
Usually, Q-PCR assays are reported to yield Cts ,29 for DNA
amountsof 10 ng or less.These guidelines, however, do not seem to
apply to FFPE-DNA templates. In our hands, the amount of 10 ng
DNA input per reaction as suggested by the manufacturer (DxS) in
order to obtain DNA control Cts ,29 was not sufficient to obtain
this Ct value. By increasing DNA input to 50 ng/reaction, the
desired Ct 29 value was obtained in some cases (Table 1), greatly
depending on DNA fragmentation (Figure 1B). The same was
observed with KRAS-TMGB as well, (Table 1, Figure 1B). The
majority of diagnostic samples and all samples with unfavorable
DNA quality yielded Cts.29, performing much worse than the
artificial template standards included to test for method perfor-
mance in the DxS kit (Figure 1C).
In comparison, samples with less fragmented DNA (favorable
DNA quality) performed optimally with all three methods tested in
this study (Figure 2). In such samples with tumor cell content
.70% (Figure 2B), dCt values with KRAS-TMGB were close to
or below 0 (Figure 2D). For such samples, the same dCt values
were yielded for a broad range of template input, from 150 ng/
reaction down to 1.5 ng/reaction (Figure 3A).
KRAS-TMGB was applied to all samples in groups A and B,
yielding informative results in 209/210 cases (99.5%), with only
one non-informative sample with very bad DNA characteristics in
group B (Table 2). DxS KRAS was mainly employed here to
validate the results obtained with KRAS-TMGB in samples where
sequencing was non-informative (Tables 1 and 2). DxS-KRAS
failed to produce interpretable results in 31.6% of the cases tested,
all of them with very fragmented DNA (Table 2). Non-
interpretable results were due to either amplification failure of
the FAM-DNA control target or Ct values .38. Repeated testing
in triplicates for 3 such samples did not improve results.
The above findings show that targeted mutation screening with
both real time PCR tests is more efficient than cycle sequencing in
identifying mutations in FFPE DNA samples; however, KRAS-
TMGB performed significantly better than DxS-KRAS with very
fragmented DNA samples (p,0.0001).
The sensitivity/selectivity of Q-PCR methods may be
,1%, but only a minority of diagnostic samples can be
analyzed at this level
As described in the Methods section, mutation calling with both
DxS-KRAS and KRAS-TMGB is based on the assessment of dCts
for the mutant vs control DNA targets. The same parameter is
used to assess method selectivity (for example, the requirement for
diagnostic methods [21] is sensitivity to detect 1% mutant cells in
an environment containing 99 wild-type cells). The lower the
percentage of mutant DNA in the sample, the higher are the dCt
values obtained and vice versa. For example, in order to achieve the
desired ‘‘1% sensitivity’’ with DxS, dCt values of ,9–10 should be
assessable. However, to analyze samples at this level of sensitivity,
Ct values for the control DNA had to be ,29, a condition that was
not met for the majority of the samples analyzed.
The results obtained with KRAS-TMGB that was standardized
in our lab (Tables 3 and 4) were in the same line. Other than
reported previously [42], herein we tested the selectivity of KRAS-
TMGB in routine clinical sample conditions, i.e., by serially
diluting mutant samples with a high tumor cell content (70%) in
KRAS wild-type tumor samples with the same DNA character-
istics. For the 1:10 dilution, a content of ,7% tumor cells was
anticipated, while for the 1:100 dilution this content would be
,7:1000. The results of this testing are shown in Figure 3B and in
Table 4. The finally used cut-off values were assessed based on the
dCt values from the 1:10 dilution assessments (Table 4), that were
remarkably close to the ones calculated from all mutant samples
(Table 3). According to these cut-off values, 7% mutant tumor cells
(or 3.5% mutant alleles) would reliably be identified in samples
with wild-type DNA Cts ,33, a condition achieved in 95%
diagnostic samples and in 1/3 of the very fragmented samples in
group B (Table 1). As can also be deduced from Table 4, if
working with DNA samples containing .70% tumor cells most of
them mutant, it would be safe to analyze samples with wild-type
DNA Cts,37. Finally, similar to DxS-KRAS, KRAS-TMGB
could detect 0.7% mutant cells with some dCT cut-offs close to 9,
as can be deduced from Table 4, again requiring DNA control Cts
,29. However, such broad dCts were not observed in any of the
52 samples fulfilling this criterion.
Table 2. Efficiency of the three methods tested for KRAS
mutation analysis on FFPE-DNA samples from the diagnostic
group A and the unfavorable control group B.
eligible informative
KRAS-TMGB 210 209 99,5%
group A 135 135 100%
group B 75 74 98,7%
fragmentation (#200 bp) 108 107 99,1%
Cycle sequencing 129/210* 61,5% 111/210 52,8%
group A 129/135 95,5% 111/135 82,2%
group B 0/75 na na
fragmentation (#200 bp) 7/108 6,5% 2/108 1,9%
Therascreen KRAS 95 65 68,4%
group A 29 28 96,6%
group B 66 37 56,1%
fragmentation (#200 bp) 81 51 62,9%
*= samples were eligible for sequencing when the corresponding PCR product
was visualized upon agarose gel electrophoresis.
na = not applicable.
doi:10.1371/journal.pone.0007746.t002
Mutation Testing on FFPE-DNA
PLoS ONE | www.plosone.org 6 November 2009 | Volume 4 | Issue 11 | e7746The dCT values for the mutant samples were significantly lower
in comparison to the non-mutant samples for each one of the 7
assays of the KRAS-TMGB test (Figure 4A). Evaluating the
presence of KRAS mutations with these assays means evaluating
the profile of dCts for all 7 assays simultaneously for the lowest dCt,
which must be lower than the cut-off value for each assay
(Figure 4B and C, Table 4). Notably, in some cases dCts close to-
or even below the cut-offs were obtained for some of the assays,
while the mutant target was clearly distinguishable by a dCt
distinctly lower among all 7 values for the same sample. Such
cross-reactivity was attributed to increased fluorescence reading
from imperfectly matched probes or primers and was observed
with DxS-KRAS as well.
Counting on Q-PCR method sensitivity may yield
erroneous results
In 3/135(2.2%) cases prospectively tested for diagnostic purposes,
all frommetastaticCRC,we had to performdoubleextractionsfrom
(a) the whole section and (b) upon macrodissection of the neoplastic
site,duetoreporteddiscrepanciesonKRASmutationstatusassessed
in different labs. Morphologically identifiable tumor cells were ,1%
in these cases. DNA control Cts varied among 30–36. Whole
sections could not be evaluated as positive for KRAS mutations,
while samples enriched in tumor cells were mutant (2 Gly12Asp, 1
Gly12Val). One such case is shown in Figure 5.
Validation of Q-PCR results
Upon external validation rounds for KRAS-TMGB results,
matching wild-type, mutation presence and type of mutation were
observed in 105/106 cases tested (99,05%). Out of the 66 samples
that yielded informative results with the DxS-KRAS-kit, mutations
were identified in 29 cases, in full concordance with the
corresponding KRAS-TMGB results (100%).
Presence and type of mutations were validated by sequencing in
111 samples. Matching results were initially observed for 109
samples. The two discrepant cases were identified as mutant with
the KRAS-TMGB test and initially as wild-type with sequencing.
One case was derived from a metastatic CRC site in the lung;
upon repeated extraction with further tumor cell enrichment, a
heterozygous T substitution could be recognized in the electro-
pherogram. The second case corresponded to a biopsy specimen
from the primary site that could not be dissected further
and contained ,10% tumor cells. This case had a mean DNA
control Ct ,35, yielded a 300bp product with the fragmentation
assay, and was evaluated as wild-type with KRAS-TMGB and
cycle sequencing in the AUTH lab. However, during external
Figure 2. Performance of a typical good quality FFPE-DNA diagnostic sample with the three methods applied for KRAS mutation
assessment. A and B: Corresponding tissue section with areas marked for macrodissection containing ,70% tumor cells. Some necrotic areas can
not be avoided but in this analogy these do not interfere with DNA extraction. The estimated number of sectioned neoplastic cells in B is ,4000. For
good quality samples, KRAS mutation assessment is reliable with any method, as shown in C (sequencing, c. 34 G.A corresponding to the G12S
change), in D (TMGB-KRAS, G12S mutation positive) and in E (DxS-KRAS, G12S mutation positive). DNA control Ct values ,29 (arrow) were yielded
with both real time PCR methods (red curves in D and E).
doi:10.1371/journal.pone.0007746.g002
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Leuven lab. Upon the 5
th attempt, the same DNA sample proved
Gly12Asp mutant with cycle sequencing as well. Gly12Asp
involves a G:A substitution that can not be regarded as an effect
of formalin fixation caused ‘‘mutations’’ as has been reported in
such tissues [43]. The difficulty to obtain a proper result with
sequencing might be due to the little amount of amplifiable DNA
in this case, which should always prompt for careful result
evaluation with this method [44].
Discussion
This study shows that the assessment of DNA fragmentation
provides important information on the amplification capacity of
the extracted FFPE-DNA and on the reliability of the obtained
results, in line with previous reports on methods involving
relatively long PCR products [30,31,45] but also short ones, as
is the case with Q-PCR assays [45]. Based on the degree of DNA
fragmentation, FFPE samples can be distinguished into those with
relatively well preserved DNA (favorable samples, roughly L of
our diagnostic cases) and those with very fragmented DNA
(unfavorable samples, J of our diagnostic cases). FFPE-DNA
quality depends on numerous, oft imponderable parameters that
can not be assessed in the diagnostic setting. For example, tissue
block age, a multi-parameter involving at least storage conditions
and continuous degradation of nucleic acids after embedding
[13,41], was vaguely related to the degree of DNA fragmentation
in our series. If information on storage conditions can not be
Figure 3. KRAS-TMGB validation on good quality FFPE DNA samples. A. The method can provide reliable results with a broad range of DNA
input, as shown here for a G12V mutant sample that was serially diluted up to 1.5 ng/reaction. dCts in all samples are kept close to 0 (safe mutation
calling with this method). Red curves, DNA control; Green curves, G12V targeting assay. B. TMGB-KRAS was sensitive to detect ,1% tumor cells in
good quality FFPE-DNA samples. Seven different mutant FFPE samples containing ,70% tumor cells (arrows) were diluted at 1:10 and 1:100 with
different wild-type FFPE-DNA samples. Amplification curve Cts of the diluted mutant DNA showed some degree of linear increase in Ct values for the
mutant target, as expected (diagonal lines).
doi:10.1371/journal.pone.0007746.g003
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type of fixative, time-to-fixation, time-in-fixative, and tissue type
are only few of the fixation-related parameters usually addressed
for their influence on DNA integrity in FFPE tissues, whereby
DNA is better preserved in buffered formalin as compared to
simple formalin [16,43,46]. Here we can only report on a limited
number of biopsy samples (n=7) that had been fixed overnight in
buffered formalin and yielded favorable DNA, as expected.
However, since the majority of the favorable DNA samples in
this study derived from large colectomy specimens that had been
fixed in simple formalin under unknown conditions, fixation in
simple formalin can not be blamed as the major determinant of
DNA fragmentation.
An intriguing issue concerning FFPE-DNA is to determine the
template amount to be added per amplification reaction, which is
particularly important for the evaluation of Q-PCR method
efficiency. As described, classic UV-measurements (concentration
and purity) may be helpful in determining DNA input for PCR in
the favorable samples only. In the unfavorable samples, UV-
concentration does not correspond to the amount of amplifiable
DNA, which is unpredictably low, as indicated by the correspond-
ing high Ct values obtained for control DNA targets (usually .33).
This explains why Q-PCR appears dependent on DNA fragmen-
tation, as noticed here in agreement with previous reports
[45,47,48]. Functional Q-PCR based tests for determining
amplifiable DNA quantity are already used in forensic medicine
and have been evaluated in FFPE-derived samples as well [47,48].
It should be noticed though, that DNA degradation may not affect
homogeneously all genomic regions [48]. For this reason, and also
because commercially available kits for Q-PCR-based DNA
quantification still need standardization [49] while increasing
cost, it seems important to determine the degree of DNA
fragmentation and to identify the unfavorable samples that need
special attention in the interpretation of genotyping results by any
molecular method.
As depicted in Table 5, all methods evaluated in this study,
including classic dideoxy-sequencing, performed optimally with
favorable FFPE-DNA; for unfavorable FFPE-DNA however,
translating into 1 in 4–5 patients, genotyping results could mostly
be obtained by targeted mutation detection with Q-PCR only.
This data is fully justified by the small amplicon size used in DxS
and TMGB KRAS assays allowing for the amplification of even
minimal amounts of preserved amplifiable DNA. Clearly, as per
assay design, both DxS-KRAS and KRAS-TMGB can only detect
and type 7 mutations in codons 12 and 13, thus probably missing
1% of KRAS mutations in CRC patients. Including assays for
KRAS codon 61 substitutions may help to further eliminating this
problem.
As an IVD-device, DxS-KRAS is a validated and standardized
test requiring minimal lab expertise. A concern about such IVD
tests is compensating for their high cost, which is partly justified by
the stringent standards set for the production of stable reagents.
However, the results obtained with this test also depend on
template input and setting the reading threshold for obtaining Ct
values, two parameters needing further standardization. The
reading threshold is of particular importance for assessing Q-PCR
sensitivity, as explained below, while it can be set very subjectively
when operating with open Q-PCR systems, such as the ABI7500
used here. In comparison, as an in-house developed method,
KRAS-TMGB is of low cost but it requires additional lab expertise
and efforts for standardization and validation. The specificity and
reproducibility of KRAS-TMGB results have been established in
this study per sequencing validation, cross-validation with DxS-
KRAS and also upon external validation in a different lab.
Technically, both Q-PCR methods seem ideal for diagnostic
applications (Table 5): minimal hands-on involvement, one-step,
one piece of equipment, quick results, easy numeric analysis, easy
troubleshooting.
Table 3. Assessment of dCt cut-off values for mutation
calling with the KRAS-TMGB test in FFPE-DNA samples.
Mutant FFPE-DNA samples validated with sequencing.
dCt mut
assay n samples mean SD
calculated cut-
offˆ
12ALA 5 20,7132 0,6340 1,1887
12ARG 3 20,9212 0,4115 0,3132
12ASP 9 0,0646 1,0771 3,2960
12CYS 2 20,0295 0,9033 2,6804
12SER 3 1,2942 1,2642 5,0868
12VAL 16 0,9986 1,3690 5,1057
13ASP 6 20,2423 0,8264 2,2368
ˆ
= mean + 3X SD.
doi:10.1371/journal.pone.0007746.t003
Table 4. Detailed assessment of dCt cut-off values for mutation calling with the KRAS-TMGB test. Mutant FFPE-DNA samples* were
diluted 1:10 and 1:100 in wild-type samples. Correspondingly, final concentrations of 7% and 0.7% tumor cells were anticipated.
dCt, undiluted dCt, 1:10 dCt, 1:100
assay mean SD mean SD calculated cut-offˆ
cut-off for use mean SD
12ALA 20,0992 0,2284 0,3386 0,2203 0,9997 ,2 1,2900 0,1531
12ARG 21,9221 0,0211 20,1348 0,1863 0,4240 ,2 1,4814 0,1318
12ASP 20,3009 0,1802 3,4264 0,1093 3,7543 4 7,6930 0,3609
12CYS 0,7338 0,1737 3,5420 0,0616 3,7269 4 5,4607 0,1741
12SER 20,1940 0,1407 4,3250 0,1537 4,7862 5 6,3535 0,4833
12VAL 0,4837 0,1256 4,3814 0,1881 4,9458 5 6,6008 0,9939
13ASP 20,6969 0,0817 2,4194 0,1543 2,8823 3 4,2344 0,3250
*= mutant samples, sequencing validated, containing approximately 70% tumor cells.
ˆ
= mean + 3X SD.
doi:10.1371/journal.pone.0007746.t004
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PLoS ONE | www.plosone.org 9 November 2009 | Volume 4 | Issue 11 | e7746Figure 4. Evaluation of KRAS-TMGB profiles. As shown in A, mutant samples have significantly lower dCT values than non-mutant ones. The
mutation status of KRAS codons 12 and 13 is evaluated based on the lowest value of the 7-dCt-profile for the corresponding mutant targets, provided
that the lowest value falls below the cut-off in each case. In some cases, dCts for the non-mutant alleles can be very low, falling within the range of
mutation calling, due to cross-reactivity (labeled as OTHER MUT). Such cross-reactions can be troublesome if evaluating each assay separately. By
contrast, if evaluating the profile of dCt values for each sample, as shown in the two examples in B with TMGB, the mutant allele can readily be
recognized. Here, on the left a sample with G12A, on the right a sample with G13D (duplicates). The dCt profiles of all samples analyzed in this study
are shown in the colormap in C.
doi:10.1371/journal.pone.0007746.g004
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importance to assess DNA quality (fragmentation and amount of
amplifiable DNA) and tumor DNA content for the accurate
interpretation of Q-PCR results. DxS-KRAS [http:// www.
dxsdiagnostics.com/Content/TheraScreenKRAS.aspx], KRAS-
TMGB ([42] and this study), as well as further Q-PCR approaches
that have been developed for point mutation assessments [25,50],
maybehighlysensitive indetectingrare mutant allelesinawild type
environment. However, this high sensitivity potential is only
applicable for samples yielding DNA control Cts below a certain
value, usually ,29. In our series, most diagnostic FFPE-DNA
samples yielded Cts.29 and were, hence, not permissible for
analysis at 1% sensitivity. In this regard, it seems necessary to
reconsider what 1% sensitivity (or selectivity) stands for when testing
FFPE tissues. In samples containing $10% tumor cells, detecting
1% mutant cells would correspond to genetic heterogeneity within
the same tumor, as previously reported for KRAS in CRCs [28,29].
Although this may be possible, we did not observe such
heterogeneity in any of the 52 cases that could be analyzed at 1%
sensitivity in our series. Hence, it seems more pragmatic and helpful
to accept cut-offs for lower sensitivity (for example, 10% [Table 5]),
so that unfavourable samples can safely be interpreted. Evidently,
this condition prompts for tumor cell enrichment and macrodissec-
tion. To avoid macrodissection counting on method sensitivity may
lead to erroneous results. Clinicians should as well be aware of this
shortcoming of the in general supersensitive Q-PCR methods under
ideal conditions.
In this study, dideoxy-sequencing was used as a reference for
mutation assessment in order to validate the results obtained by Q-
PCR assays, especially KRAS-TMGB that had not previously
been validated in the diagnostic setting. In this sense, dideoxy-
sequencing served its purpose. However, with an efficiency of
82.2%, which may be comparable [24] or higher [23] than
reported elsewhere but remains low for a diagnostic test, and with
the technical disadvantages described in Table 5, despite the low
cost, dideoxy-sequencing can hardly be considered for point
mutation detection in the FFPE diagnostic setting. Dideoxy-
sequencing still remains the golden standard for DNA analysis,
although mutations may be missed in cases with low representa-
tion of tumor DNA, as exemplified in two cases in this study.
Including as much as possible DNA template for more reliable
sequencing results [44] would perhaps help in less fragmented
samples, while discrepant results on KRAS mutation status
assessed with sequencing and with DxS-KRAS have recently
Figure 5. Typical example of a diagnostic case with very low content in neoplastic cells. If macrodissection is avoided in such cases,
erroneous results are likely to be obtained. A, whole section of the CRC metastatic site (M) surrounded by normal liver (L). Circled areas are marked for
macrodissection. In B, the metastatic site is largely composed of necrotic (N) and calcified (Ca++) elements within a loose stroma (s), while neoplastic
cells (asterisks) correspond to ,,1% in the whole section (A) and to ,10% in the macrodissected areas (B). Two DNA samples were extracted from
this specimen, one upon macrodissection and one from the whole section. As shown in C, although both DNA samples were of the same unfavorable
quality (DNA control Ct,34.5), it was possible to identify the G12D mutation in the macrodissected sample, while the sample obtained from the
whole section appeared as wild type. Arrow in C, Ct=29.
doi:10.1371/journal.pone.0007746.g005
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warranted when performing validation trials with dideoxy-
sequencing as the golden standard to determine the specificity of
methods with higher mutation detection efficiency on FFPE-DNA
templates. In comparison to dideoxy-sequencing, pyrosequencing
seems to be much more efficient in analyzing 60–80 nt long
sequences from FFPE-DNA templates. Pyrosequencing assays for
diagnostically relevant KRAS, BRAF and PIK3CA mutations
have been developed [52,53,54]. Pyrosequencing is simpler, faster
and more sensitive than dideoxy-sequencing but, as any
sequencing method developed so far, it remains a complex
method. This fact along with the required instrumentation and
high-lab expertise, may have contributed in the currently limited
application of this method in Europe.
Involving both classic histology and molecular testing on FFPE-
DNA, the assessment of drug-response-predictive point mutations
in solid tumors is a diagnostic practice still in its infancy. If anti-
cancer drugs are labelled for specific mutations, robust and reliable
diagnostic tests are needed for the identification of the altered
genotypes in tumor material. In the case of hot-spot point
mutations, as exemplified here with KRAS in CRC, targeted
mutation detection with Q-PCR methods appears as the ideal
approach. Because these methods are easily applicable (the IVD
DxS-KRAS, in particular) and highly efficient, it is expected that
their use will spread dramatically, especially if more hot-spot point
mutations enter diagnostics [55,56,57]. Because, however, FFPE-
DNA quality is unpredictable, it is fundamental to consider DNA
degradation status and amplification capacity, as well as tumor
DNA content in order to interpret Q-PCR results and provide
accurate information for clinical use. Failure to embed these
parameters in molecular diagnostics may result in erroneous
interpretations and ultimately harm clinical oncology practice in
the frame of targeted therapy.
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